We have recently developed a sensitive and specific urine-based antigen detection ELISA for the diagnosis of visceral leishmaniasis (VL). This assay used rabbit IgG and chicken IgY polyclonal antibodies specific for the Leishmania infantum proteins iron superoxide dismutase 1 (Li-isd1), tryparedoxin1 (Li-txn1) and nuclear transport factor 2 (Li-ntf2). However, polyclonal antibodies have limitations for upscaling and continuous supply. To circumvent these hurdles, we began to develop immortalized monoclonal antibodies. We opted for recombinant camelid VHHs because the technology for their production is well established and they do not have Fc, hence providing less ELISA background noise. We report here an assay development using VHHs specific for Li-isd1 and Li-ntf2. This new assay was specific and had analytical sensitivity of 15-45 pg/mL of urine. The clinical sensitivity was comparable to that obtained with the ELISA assembled with conventional rabbit and chicken antibodies to detect these two antigens. Therefore, similar to our former studies with conventional antibodies, the future inclusion of VHH specific for Li-txn1 and/or other antigens should further increase the sensitivity of the assay. These results confirm that immortalized VHHs can replace conventional antibodies for the development of an accurate and reproducible antigen detection diagnostic test for VL.
| INTRODUC TI ON
Accurate diagnosis of active visceral leishmaniasis (VL) both in humans and dogs is still a difficult task. Because VL is an insidious and slow progressing pathology, clinical diagnosis is mostly achieved at the later stages of the disease when marked signs of anaemia and hepato/splenomegaly become present. During this phase, the parasites (or their molecules) can be detected in biopsies of liver, spleen and bone marrow. Unfortunately, these tests are at best 60% sensitive. [1] [2] [3] Due to the limitations of these methods (aggressive risky sample collection and low sensitivity), the presence of antiparasite antibodies is routinely used as a marker of infection. [3] [4] [5] [6] [7] [8] Overall, the reported performances of these tests indicate that they have good sensitivity for the diagnosis of VL in both symptomatic and asymptomatic humans and dogs. However, due to cross-reactions with other infectious agents (eg, Leishmania agents of cutaneous/mucosal leishmaniasis, Trypanosoma cruzi and Trypanosoma brucei), and the difficult choice of a suitable cut-off, these conventional serological tests are less specific than PCR assessment of parasites in biopsy or blood specimens. 5 Moreover, these antibody tests do not discriminate active disease from either subclinical infection or cured individuals because the antibodies can circulate for years after cure. In addition, these tests have several other limitations, including inability to predict response to treatment and very low sensitivity (57.4%) in patients co-infected with HIV. [9] [10] [11] An antigen detection test for VL was developed approximately 10 years ago as an interesting alternative for the diagnosis of active VL. This assay is a latex agglutination test (KAtex) based on leishmanial antigen detection in urine of patients with VL. This test detects a mixture of leishmanial carbohydrate complex antigens using latex beads adsorbed with specific polyclonal rabbit antibody. [12] [13] [14] [15] [16] Preliminary studies using urine of VL patients demonstrated the presence of leishmanial antigen in active disease followed by its disappearance after successful treatment. 17 However, recent studies involving VL patients co-infected with HIV have shown that the sensitivity of KAtex varied from 47.7% to 85.7% and specificity from 96% to 98.7%. 18 These conflicting results can perhaps be explained on the grounds of uncontrolled specificity and sensitivity (affinity/ avidity) of the anticarbohydrate antibodies used in the test. The carbohydrate preparation involves the growth of leishmania promastigotes followed by several biochemical purification steps. 17 These procedures usually generate a mixture of related and unrelated products. Consequently, this antigenic preparation, when used to produce a key reagent (antibody) for the test development, stimulates a mixture of a variety of antibody specificities. Therefore, the production of a test assembled using a heterogeneous antibody population is, by definition, difficult to standardize under standard operating procedures (SOP).
An alternative to native carbohydrates, microbial protein antigens are interesting molecules to circumvent the above restrictions.
Protein epitopes are better defined, and recombinant proteins or synthetic peptides are easily obtainable thus facilitating production and upscaling of reliable and reproducible specific antibodies.
Using this premise, we have recently identified the Leishmania infantum proteins iron superoxide dismutase 1 (Li-isd1), tryparedoxin1
(Li-txn1) and nuclear transport factor 2 (Li-ntf2) in the urine of VL patients, presumably shed from the parasite during active VL. [19] [20] [21] These antigens or biomarkers represented unique and promising candidate molecules for the development of an antigen detection test for the diagnosis of active VL. In our preliminary pilot studies using a capture ELISA assembled to detect these three antigens in urine samples of confirmed VL patients from Brazil, the assay was >95% sensitive and 100% specific. Unfortunately, the polyclonal antibodies that were produced in rabbits and chicken to develop the test are not adequate for mass scale production of the final test.
Ideally, the antibodies should be immortalized reagents.
Camelid single-domain recombinant antibodies (sdAbs) offer a new approach to generating such renewable diagnostic reagents.
With a molecular weight of approximately 13 kDa, these highaffinity, single-domain variable fragments of heavy-chain antibodies (VHHs) have the ability to refold and retain binding activity after denaturation. 22 Moreover, large amounts of VHHs can be produced by standard recombinant protein expression in Escherichia coli.
Therefore, VHHs are very desirable immunoreagents.
22-24
Here, we report the production, characterization and initial clinical validation of immortalized camelid VHHs specific for the L. infantum biomarkers iron superoxide dismutase1 (Li-isd1) and nuclear transport factor 2 (Li-ntf2). The results confirm that these antibodies are promising and useful reagents for development and mass scale production of a feasible antigen detection assay for the accurate diagnosis of VL. 
| MATERIAL AND ME THODS

| Clinical specimens
| Immunization of alpacas
Alpacas were obtained locally and maintained on pasture.
Immunizations and bleeding procedures followed National Institute were produced and purified as we have previously described. 20 The alpacas were immunized with a pool of the three antigens (100 μg each) by five successive multisite subcutaneous (SC) injections at 3-week intervals. For the first immunization, the antigens were in alum/CpG adjuvant, and subsequent immunizations contained only alum as an adjuvant. Fifteen days after the 4th immunization, alpacas were bled for serology.
| VHH display library preparation from lymphocytes of immunized alpacas
Blood was obtained from the two alpacas 7 days after the fifth immunization followed by lymphocyte purification and RNA preparation, which was performed using the RNeasy kit (Qiagen, Valencia, CA, USA). A VHH display phage library was prepared as described previously, 25 yielding a library (JRB-2) having a complexity of ~1 × 10 7 independent clones with >95% containing VHH inserts.
| Identification and purification of VHHs
Phage library panning, phage recovery and clone fingerprinting were performed as previously described. 26 
| Expression and purification of VHHs in
Escherichia coli
Expression and purification of recombinant thioredoxin/VHH fusion proteins containing hexahistidine were performed as previously described. 28 All recombinant VHHs were expressed with a carboxyl- were developed with TMB substrate and read at 450 nm.
| Statistical analysis
Statistical significance was determined by unpaired t test for comparisons between capture ELISA results obtained for VL patients and healthy subject control groups. Comparisons were performed using the Mann-Whitney rank-sum test (P values <0.05 were considered statistically significant).
| RE SULTS
| Generation and purification of VHHs specific for Li-isd1, Li-txn1 and Li-ntf2
Subsequent to the immunization of the alpacas used to generate the VHHs, the antibody immune response was monitored by direct ELISA. Both alpacas responded with high antibody titres to Li-isd1, Li-txn1 and Li-ntf2 (>1/62 500). Based on our prior experience 22, 25 these are fully acceptable responses for the generation of recom- 
| Li-isd1
About 80% of the clones displayed significant binding (>2× background) for Li-isd1 by ELISA, and about 50% of the clones displayed strong binding (>10-30× background), demonstrating that the antigen had elicited a robust VHH response. Forty-five-positive clones were picked for DNA fingerprinting and 13 showed unique fingerprints. These clones were selected for DNA sequencing. Sequencing showed that the 13 VHHs clustered into five groups that clearly derive from B cells having a common origin. The VHH producing the strongest apparent target recognition was selected from each of the five homology groups. These five VHHs had unique complementarydetermining regions (CDRs), suggesting they do not have common B-cell origins.
| Li-txn1
The panning and selection process proceeded poorly despite the strong antibody titres observed in the sera of the immunized alpacas. Only one VHH could be expressed that showed binding to
Li-txn1, although with poor affinity. Moreover, this clone was not specific for Li-txn1. Therefore, this marker was deprioritized for further evaluation.
| Li-ntf2
About 25% of the affinity-selected clones displayed significant bind- 
| Production of high-affinity homodimer and heterodimer of selected VHHs for assay development
Next, we produced a series of homodimers and heterodimers of the selected VHHs. VHH homo and heterodimers are known to increase the affinity of their interaction with the target molecules.
In addition, the heterodimer recognizes two epitopes in the native target molecules thus increasing the overall ability of the reagent to detect the biomarker. The homodimers and heterodimers were obtained using synthetic genes encoding either a duplicate VHH (homodimer) or two VHHs recognizing different epitopes of the target biomarker (heterodimer). After expression and purification, using a conventional capture ELISA, these reagents were tested in varied combinations, either as capture or detection antibodies. The VHH dimers that provided the best signal to noise OD for each of the biomarkers were selected for further clinical assay development. For
Li-isd1-specific clones, we selected JRD-C1/JRD-C1, a homodimer expressed as JRD-C1/JRD-C1/myc, and JRD-E5/JRD-E9, a heterodimer expressed as JRD-E5/JRD-E9/E-tag. VHHs recognizing only two nonoverlapping Li-ntf2-specific epitopes were identified, so heterodimers could not be used as components of a Li-ntf2 capture ELISA.
Therefore, we constructed homodimers only of the two anti-Li-ntf2 VHH clones. 
| Clinical validation of the assay assembled with VHHs
In order to begin the validation of the VHHs specific for Li-isd1
and Li-ntf2 as immortalized reagents for the development of a VL diagnostic test, we performed a capture ELISA assembled with these reagents and used urine samples from 24 patients with confirmed VL from Minas Gerais State, Brazil, and from 12 healthy control subjects from this endemic area for the disease. Urine samples from VL patients were collected prior to initiating VL therapy. In addition, the samples were also tested comparatively using the Li-isd1 and Li-ntf2 assays that we have previously developed. 19, 20, 30 For this assay, the capture ELISA is assembled with conventional rabbit and chicken antibodies. For the VHH-based assays, we used the reagents described in Figure 2 ; that is for the assay to detect Li-isd1, we used the homodimer JRD-C1/JRD-C1-C1/myc as capture and the heterodimer JRD-E5/JRD-E9/Etag as the developing reagent. For the assay to detect Li-ntf2, we used the homodimer JRO-H8/JRO-H8/myc as capture and the homodimer JRF-E3/JRF-E3/E-tag as the developing reagent. Using a standard cut-off value calculated as the average of the results for the samples from the healthy control subjects plus 3 SD, 10 (41%) VL samples tested positive using the assay assembled with the anti-Li-isd1VHH reagents ( Figure 3 ). In contrast 8 (33%) VL samples tested positive using the assay assembled with conventional antibodies (affinity-purified IgY as capture and biotin-labelled rabbit IgG as developing reagent). Although the sensitivity of either assay is not high enough to warrant a final test for the diagnosis of VL, it indeed confirms our previous results using conventional anti-Li-isd1 antibodies, 19, 20 which was approximately 30%. A highly sensitive test (>98%) was only achieved when we used a multiplexed assay assembled to detect, in addition to Liisd1 the two other L. infantum-specific biomarkers. Importantly,
F I G U R E 2 Sensitivity of capture ELISAs assembled with VHH for detection of the proteins Li-isd1
and Li-ntf2 spiked in buffer as well as in urine samples of normal healthy subjects. Capture VHH JRD-C1/JRD-C1-C1/myc (anti-Li-isd1) or JRO-H8/JRO-H8/myc (anti-Li-ntf2) at 2 μg/ mL was used to coat the ELISA plates. Wells were then incubated with various concentrations of Li-isd1 or Li-ntf2 diluted either in buffer plus 1% BSA or in urine from normal healthy subjects followed by incubation with E-tag-labelled developing VHH JRD-E5/JRD-E9 (anti-Liisd1) or JRF-E3/JRF-E3 (anti-Li-ntf2). Reactions were developed after addition of peroxidase-labelled anti-E-tag plus the substrate H 2 O 2 and the chromophore TMB. Results are expressed as OD read at 450 nm. Same results were obtained using ELISA assembled with conventional rabbit IgG and chicken IgY antibodies (not shown) 
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Buffer Urine the results illustrated in Figure 3 show that most samples that were positive using the assay assembled with the VHHs were also positive with the assay assembled with conventional antibodies.
However, a few samples among the disease group were positive only for one of the two tests. To experimentally confirm the complementation, we next assembled a "duplexed" assay coating the plates with both JRD-C1/ JRD-C1-C1/myc and JRO-H8/JRO-H8/myc homodimers and developing the reaction with a pool of JRD-E5/JRD-E9/E-tag plus JRF-E3/ JRF-E3/E-tag. This duplexed assay was then used to test the urine samples from VL patients, from both healthy control subjects and from non-VL patients who have other infectious diseases (cutaneous leishmaniasis, Chagas' disease, schistosomiasis and tuberculosis). The results are illustrated in Figure 6 and confirm the predicted complementary illustrated in Figure 5 . In fact, the overall sensitivity of the duplexed assay was slightly superior to that of the predicted sensitivity (66.6% × 54.2%), which could be due to incremental or summative OD signals in borderline results of urine samples performed with the individual VHHs. In addition, the results obtained with the duplexed assay further confirms the specificity of the test in that no positive samples were seen with urine from healthy control subjects as well as from patients having several infectious diseases other than VL.
Together, these findings agree with our previous observations that showed that a multiplexed assay will have excellent sensitivity and specificity for the diagnosis of VL. 
VL patients Controls
Anti-Li-isd1 VHH Anti-Li-isd1 Conventional Abs F I G U R E 4 Antigen detection capture ELISA assembled with VHHs for the identification of Li-ntf2 in urine of VL patients and controls. ELISA plates were coated with either JRO-H8/JRO-H8/myc (2 μg/mL) or purified IgY anti-Li-ntf2 antibody (1 μg/mL). After overnight incubation with patients or control urine samples, plates were washed and wells were incubated with E-tag-labelled developing JRF-E3/JRF-E3 or biotin-labelled rabbit IgG anti-Li-isd1 antibody. Wells corresponding to reactions with VHHs were next incubated with peroxidase-labelled rabbit anti-E-tag antibody. Wells incubated with biotinylated IgG were next incubated with streptavidin-peroxidase. The substrate H 2 O 2 and the chromophore TMB were then added followed by OD reading at 450 nm. Samples from VL patients and from controls were from Belo Horizonte, MG, Brazil. Dashed lines represent the cut-off values calculated as described in the text. These are representative results of at least three experiments performed at different times with the same urine samples and same capture ELISA. VL, visceral leishmaniasis 
Anti-Li-ntf2 VHH Anti-Li-ntf2 Conventional Abs F I G U R E 5 Compiled results of capture ELISA assembled with VHHs or conventional Abs for the identification of the proteins Li-isd1 and Li-ntf2 in urine of VL patients and controls. Note that several samples were positive only with either one of the VHH (A) or conventional Abs (B) assays, hence supporting the development of a multiplexed assay to increase the clinical sensitivity of the test. Also, the overall sensitivity of the compiled assays was highly comparable between VHH and conventional Abs assays (54.2% and 58.3% for VHH and conventional Abs, respectively). VL, visceral leishmaniasis 
| D ISCUSS I ON
Over the past years, using mass spectroscopy, we have shown that protein antigens from pathogens such as Mycobacterium tuberculosis and L. infantum can be detected in urine of patients with pulmonary tuberculosis and VL, respectively. The discovery of these pathogen proteins led us to the development of urine-based antigen detection diagnostic tests for these diseases. 19, 20, [30] [31] [32] [33] Capture ELISAs assembled with polyclonal antibodies raised in rabbits, and chicken have been used as proof of concept for the development of a urine-based diagnostic test. This overall approach has proven to be a reliable discovery of pathogen biomarkers strategy, particularly for VL. A multiplexed assay based on three of the discovered biomarkers could be developed and shown to be highly sensitive and specific for the diagnosis of VL. 19, 20, 30 However, a possible hindrance for upscaling and commercial production of this test exists as it relies on polyclonal antibodies. Conventional monoclonal antibodies (mAb) or recombinant single-domain antibodies (sdAbs) are existing and proven alternatives to circumvent this limitation.
Here, we report our preliminary results on the use of sdAbs produced to the L. infantum antigens Li-isd1 and Li-ntf2 that we previously described as biomarkers of VL. We opted for the production of the immortalized recombinant camelid VHH because the technology for the production of such unique monoclonal antibodies is well 
Clinical sensitivity and specificity of a capture duplexed ELISA assembled with both Li-isd1 and Li-ntf2 VHHs. ELISA plate wells were coated with a pool of VHH JRD-C1/JRD-C1-C1/myc (anti-Li-isd1) and JRO-H8/JRO-H8/myc (anti-Li-ntf2) VHHs following by blocking and overnight incubation with patients or control urine samples. Plates were washed, and wells were incubated with a pool of the E-tag-labelled developing VHHs JRD-E5/JRD-E9 (anti-Li-isd1) plus JRF-E3/JRF-E3 (anti-Li-ntf2). Wells were next incubated with peroxidase-labelled rabbit anti-E-tag antibody. The substrate H 2 O 2 and the chromophore TMB were then added followed by OD reading at 450 nm. Samples from VL patients, n = 24; CL (cutaneous leishmaniasis) n = 6; CD (Chagas disease), n = 6; Sch (schistosomiasis), n = 6; and TB (tuberculosis), n = 12 were from Belo Horizonte, MG, Brazil. Healthy controls, n = 6 were from local donors. Dashed line represents the cut-off values calculated as described in the text. These are representative results of at least three experiments performed at different times with the same urine samples. VL, visceral leishmaniasis that further clarification of whether the lack of clone detection was indeed due to low frequency of B cells or was due to conformational changes was beyond the scope of the manuscript, we deprioritized the generation of anti-Li-txn1 VHH in the present pilot study.
The capture ELISAs assembled with either anti-Li-isd1 or anti-
Li-ntf2
VHHs showed similar biochemical sensitivity to that of our former ELISA assembled with chicken and rabbit conventional antibodies. This is a critical step for the development of a urine-based antigen detection assay because the concentration of the pathogen's biomarker in this clinical sample is very low. Our former studies indicated that an assay sensitivity equal or higher than 100 pg/ml of the analyte in the urine sample is not sensitive enough to be used in clinical settings. We are confident that because the sensitivity of both capture ELISAs assembled with the VHHs produced in the present study was ~15-45 pg/mL, these reagents are compatible with the development of a sensitive clinical diagnostic test for VL. Moreover, and importantly, the binding of the VHHs to their specific targets was not inhibited by human urine.
The initial clinical validation of the ELISAs assembled with VHHs clearly showed that the selected and engineered reagents have a clinical sensitivity and specificity for the diagnosis of VL that is similar to that of the assay developed with conventional antibodies. At this point, the overall sensitivity of the duplexed VHH assay (66.6%) is not sufficient for the development of a final test for the diagnosis of VL. However, these results are consistent with our former studies that indicated that a highly sensitive test requires the simultaneous detection of at least three VL biomarkers, either separately or in a multiplexed formatted test. 19 Therefore, the inclusion of VHHs specific for other leishmanial markers, for example Li-tnx1, should increase the sensitivity of the assay to accepted clinical levels. Moreover, we have recently discovered and characterized the clinical utility of four new Leishmania donovani markers (manuscript in preparation). Hence, we are confident that the addition of new VHHs specific for these additional markers will result in a development of a highly sensitive assay for the diagnosis of VL.
Finally, we believe that this assay, once optimized for higher sensitivity, will be of great utility not only for the diagnosis of active VL but also as an important tool to monitor the treatment efficacy of this disease. In fact, we have preliminary evidence of this utility using an ELISA assembled with conventional rabbit and chicken antibodies. 30 This observation supports the suggestion that the assay sensitivity or antigen concentration in the urine is correlated with the pathogen's burden in the target organs. Therefore, in theory, it is possible that because urine from infected individuals contain variable amounts of pathogen antigens that a quantitative assay may be used to correlate different clinical forms and/or severity of the disease, for example asymptomatic and active VL.
In conclusion, altogether, the results confirm that VHH can replace conventional antibodies for the development of an antigen detection diagnostic test for VL. Importantly, because VHHs are immortalized reagents, they circumvent a practical and major limitation of conventional antibodies, that is the upscaling and continuous commercial supply of these reagents.
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